Loading…
← CockpitCompetitor Analysis › VREX Varex Imaging CorporationOpen in the cockpit ↗

Varex Imaging CorporationVREXCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 92
Mkt cap
$771M
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$13.1M
20-day average traded
Fwd P/E
19.9×
forward earnings
ROIC−WACC
-1.6 pp
WACC 8.7%
Hurdle
n/a
no reverse DCF
Next earnings
6 days
24 Nov 2026
Close · USD$18.15
1D+0.3%
1W-1.3%
1M-1.4%
3M-1.8%
6M+79.2%
YTD+55.8%
1Y+58.8%
ATR %0.5%
Beta0.91
52w lowhigh2.6% off high

What Varex Imaging does

Employees: 2,400

Varex Imaging at a glance

Size Varex Imaging (VREX) is a United States Health Care company (Medical Specialties) with a market value of $771M, the 2397th largest of 3,085 United States companies the cockpit tracks. Shares closed at $18.15 on 18 Nov 2026.

Performance Over six months the shares gained 79.2%, against -17.5% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 5.3% over the last twelve months (peer median +12.6%); the operating margin is 8.3% (peer median 12.8%).

Valuation It trades at 19.9× forward earnings against a peer median of 20.0× (7th cheapest of 14).

Capital Return on invested capital runs 1.6 points below its cost of capital (8.7% WACC).

Short interest Short interest is 4.8% of the free float (30 Oct 2026).

Next results Next results expected around 24 Nov 2026 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026VREX 179Peer median 84
Six months, rebased to 100: Varex Imaging against the median of its 20 peers (local-currency closes).

Varex Imaging financials

Reported figures in USD; fiscal year ends 2025-09-30. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$865M$845M$811M$893M$859M
Revenue growth—+4%-9%+4%—
Gross profit$297M$290M$257M$290M$284M
EBITDA$99.5M$93.3M$63.2M$110M$124M
Net income$22.1M-$70.3M-$48.8M$48.2M$30.3M
Free cash flow-$20.2M$17.6M$18.1M$87.7M-$4.40M
Capital expenditure$31.5M$22.9M$26.9M$20.7M$21.3M
Total debt$379M$402M$477M$470M$437M

Quarterly statements and history in the cockpit →

Varex Imaging competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%-10%0%+10%13022190CTKBMLABBBNXSETL300463688108002950300453603108301367688179096530AMSMCAP688805VREX6-month return →1-month return →
Up and to the right = strong over both horizons. Varex Imaging is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×13022190MLAB300463688108300453603108301367096530AMSVREXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Varex Imaging is the large dot.

Varex Imaging competitors and peer comparison

How Varex Imaging compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Varex Imaging against its 20 peers (data as of 18 Nov 2026)
MeasureVREXPeer medianRank in peer set
1-month return-1.4%-8.5%7th highest of 21
6-month return+79.2%-17.5%2nd highest of 21
Distance from 52-week high-2.6%-41.0%2nd highest of 21
Revenue growth (TTM)+5.3%+12.6%7th lowest of 21
Operating margin8.3%12.8%8th lowest of 21
Forward P/E19.9×20.0×7th cheapest of 14
ROIC minus cost of capital-1.6 pp-0.6 pp11th highest of 21
EV / EBITDA10.7×14.7×3rd cheapest of 9
Net debt / EBITDA2.8×-1.5×most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Varex Imaging VREXUnited States$771M+79%+5%8%19.9×n/an/a
LifeTech Scientific 1302.HKHong Kong$771M-30%+1%12%19.8×9.6%+15.5%
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$768M-16%+39%25%14.4×3.8%+105.8%
Cytek Biosciences CTKBUnited States$774M+57%+6%-21%n/an/an/a
Mesa Laboratories MLABUnited States$775M+33%+2%10%11.5×21.3%+13.2%
Beta Bionics BBNXUnited States$779M+42%+44%-73%n/an/an/a
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%n/an/an/a
Maccura Biotechnology 300463.SZChina$756M-18%-1%-4%421.0×7.9%-10.2%
Sino Medical Sciences Technology 688108.SSChina$753M-41%+22%19%60.0×27.9%+9.9%
Allmed Medical Products 002950.SZChina$747M-32%+14%8%n/an/an/a
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%16.2×-1.9%+11.8%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%20.5×20.3%-0.2%
InMode INMDUnited States$741M-8%+2%18%9.8×-10.8%+12.4%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%n/an/an/a
BMC Medical 301367.SZChina$737M-17%+37%17%18.7×-1.5%+15.6%
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%27.4×17.1%+24.2%
Seegene 096530.KSSouth Korea$808M-26%+13%13%20.0×-6.7%-15.9%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%20.7×20.0%+21.4%
MedCap MCAP.STSweden$811M-4%+17%15%25.8×2.7%+20.9%
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%n/an/an/a
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%n/a35.6%+17.1%

Questions

Which companies are Varex Imaging's closest peers?
The cockpit's peer set: LifeTech Scientific (1302.HK), Zylox-Tonbridge Medical Technology (2190.HK), Cytek Biosciences (CTKB), Mesa Laboratories (MLAB), Beta Bionics (BBNX), Standard Engineering Technology (SETL.NS), Maccura Biotechnology (300463.SZ), Sino Medical Sciences Technology (688108.SS).
Is Varex Imaging expensive compared with its peers?
On forward p/e it trades at 19.9× against a peer median of 20.0×, 7th cheapest of 14 in its peer set.
How has Varex Imaging stock performed?
Over six months to 18 Nov 2026 the shares returned +79.2% against -17.5% for the median peer; over one year +58.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.